Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter syndrome with TP53 deletion. Delaying ibrutinib until cycle 2 was used as a ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...

Fixed-duration Venclexta/Gazyva or Venclexta/Imbruvica therapies show noninferior progression-free survival compared to continuous Imbruvica in untreated CLL patients. Three-year progression-free ...

The U.S. Food and Drug Administration (FDA) has approved IMBRUVICA ® (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL). The approval is based on data from the ...

Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...

Overwhelmed. That’s how some people describe chronic lymphocytic leukemia (CLL) diagnosis. Especially when you’re told to “watch and wait” rather than start treatment. Over 23,000 people in the U.S.